ClinicalTrials.gg
RecruitingNCT07157475Updated Mar 23, 2026

Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors

An observational study in Peripheral Arterial Disease(PAD), sponsored by Wroclaw Medical University. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Wroclaw Medical University · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.

Started
2025
with 4 others
Observational
3 of 31
1 open now
Registered
30th of 31
by date

Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is one of 5 that started in 2025, is one of 3 observational ones, and was the 30th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Peripheral Arterial Disease with a site in Poland, or all of them as a file.
02

Study summary

The study is observational and involves patients (pts) with peripheral arterial occlusive disease (PAD) who have undergone lower limb revascularization procedures. Patients who are at least one year post-procedure will be contacted by phone and asked whether any cardiovascular complications occurred during that period, specifically major adverse cardiovascular events (MACE) or major adverse limb events (MALE), and whether they had been taking sodium-glucose co-transporter 2 inhibitors (SGLT2-i, "flozins") during the year following the procedure. The results from the group of pts who, for any reason, received SGLT2-i treatment after the vascular procedure (including those who had initiated treatment before surgery) will be compared to the results from the group of patients who did not receive such treatment, with regard to the occurrence of the aforementioned complications.

Read the detailed description

Project Objective: To assess the impact of SGLT2 inhibitors (SGLT2-i) on vascular complications in patients undergoing peripheral revascularization.

Specific Objective: To evaluate the incidence of 3-point MACE* (Major Adverse Cardiac Events) and MALE** (Major Adverse Limb Events) following vascular surgical procedures (both open and minimally invasive), performed in patients treated with SGLT2- i vs controls ( non-treated pts).

Observation Period: One year - assessment at 30 days, 3 months, and 1 year post-procedure.

Definitions for:

* MACE = Non-fatal myocardial infarction (MI),Non-fatal stroke involving the central nervous system (CNS), Cardiovascular death

** MALE = Untreated restenosis or deterioration in patency of a previously revascularized vessel , Reintervention in the revascularized segment due to impaired patency, Amputation (either above or below the knee) of the revascularized limb.

Demographic and clinical data will be obtained from the medical records of patients hospitalized in three vascular surgery departments (Wrocław, Poznań, Warsaw), while information regarding MACE , MALE, and the use of SGLT2-i will be collected via telephone interviews with the patients (or their family members, if the patient is deceased).

The number of MACE and MALE incidents during the year following the procedure will be compared between the two groups.

03

Conditions studied

  • Peripheral Arterial Disease(PAD)

Keywords

  • flozins
  • SGLT2i
  • peripheral arterial disease
  • revascularisation
  • MACE
  • MALE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The analyzed cases will involve patients from three major vascular clinics located in Wrocław, Poznań, and Warsaw.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Peripheral vascular procedure ( Conventional surgical procedure or minimally invasive procedure) due to acute or chronic ischemia
  • Use of SGLT2 inhibitors (applies only to the group exposed to flozins) for at least 3 months prior to the vascular procedure (the indication for initiating the drug is irrelevant: chronic kidney disease [CKD] / cardiac reasons / diabetes), or immediately after the vascular procedure
  • Ability to determine the patient's outcomes within a minimum of 30 days up to 1 year following the vascular procedure

Exclusion criteria

Exclusion Criteria:

  • Vascular injury as the reason for the procedure
  • Amputation due to causes other than ischemia (e.g., cancer, neuropathy, trauma without coexisting ischemia)
  • Planned revascularization procedure other than for the lower limbs at the time of hospital discharge (e.g., coronary or carotid arteries)
  • Planned ischemia-related amputation or reoperation of the operated limb at the time of hospital discharge
  • Planned other major surgical procedure with high cardiovascular risk at the time of hospital discharge
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients after vascular surgery treated with flozins

    Patients aged ≥18 years who have undergone vascular surgery (either open or minimally invasive procedures) and, for any reason, were treated with SGLT2 inhibitors ("flozins") during the one-year follow-up period after the procedure.

    Drug: Treatment with SGLT2 inhibitors (flozins)

  • Patients after vascular surgery with no exposure to flozins (controls)

    Patients aged ≥18 years who have undergone vascular surgery (either open or minimally invasive procedures) and were not exposed to SGLT2 inhibitors ("flozins") during the one-year follow-up period after the procedure.

Interventions

  • DrugTreatment with SGLT2 inhibitors (flozins)

    Drug page: SGLT2 inhibitorsStudies of SGLT2 inhibitorsSGLT2 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients received SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) as part of their routine clinical care during the 12-month follow-up period after elective or urgent lower limb revascularization procedures. The study does not assign treatment; medication use occurred independently of the study protocol.

06

What researchers measure

Primary outcomes

  1. MACE (Major Adverse Cardiovascular Events) and MALE (Major Adverse Limb Events)-Number of Participants Experiencing MACEor MALE

    MACE is defined as a composite of : Non-fatal myocardial infarction (MI); Non-fatal stroke involving the central nervous system (CNS); or Cardiovascular death MALE is defined as a composite of : Untreated loss or deterioration of patency in a previously revascularized vessel; Repeat intervention in a revascularized segment due to impaired patency, or Amputation (above or below the knee) of the revascularized limb Unit of Measure: Number of participants with at least one event

    Time frame: 12 months from the vascular intervention

Secondary outcomes

  1. Non-fatal Myocardial Infarction (MI)

    Non-fatal myocardial infarction (MI), Unit of Measure: Number of participants Non-fatal stroke involving the central nervous system (CNS) Cardiovascular death Untreated loss or deterioration of patency in a previously revascularized vessel Repeat intervention in a revascularized segment due to impaired patency Amputation (above or below the knee) of the revascularized limb

    Time frame: 12 months from the vascular intervention

  2. Non-fatal Stroke Involving the Central Nervous System (CNS)

    Non-fatal Stroke Involving the Central Nervous System (CNS), Unit of Measure: Number of participants

    Time frame: 12 months from the vascular intervention

  3. Cardiovascular Death

    Cardiovascular Death, Unit of Measure: Number of participants

    Time frame: 12 months from the vascular intervention

  4. Loss or Deterioration of Patency in a Previously Revascularized Vessel

    Loss or Deterioration of Patency in a Previously Revascularized Vessel, Unit of Measure: Number of participants

    Time frame: 12 months from the vascular intervention

  5. Repeat intervention in a revascularized segment due to impaired patency

    Repeat intervention in a revascularized segment due to impaired patency; Unit of Measure: Number of participants and number of limbs

    Time frame: 12 months from the vascular intervention

  6. Amputation of the revascularized limb

    Amputation (above or below the knee) of the revascularized limb; Unit of Measure: Number of participants and number of limbs

    Time frame: 12 months from the vascular intervention

Other outcomes

  1. Additional secondary endpoint- Surgical site infection (SSI)

    Surgical site infection occurring after the index vascular intervention. Unit of Measure: Number of participants

    Time frame: 12 months from vascular intervention

  2. Additional secondary endpoint- Significant bleeding

    Clinically significant bleeding events as assessed by treating physician (according to established clinical criteria). Unit of Measure: Number of participants

    Time frame: 12 months from vascular intervention

  3. Additional secondary endpoint- Kidney injury

    Acute kidney injury occurring after vascular intervention, defined according to KDIGO (Kidney Disease: Improving Global Outcomes) criteria. Unit of Measure: Number of participants

    Time frame: 12 months from vascular intervention

  4. Additional secondary endpoint- Reintervention in the Same Vascular Segment

    Readmission and repeat procedure in the same vascular segment due to impaired patency. Unit of Measure: Number of participants and number of limbs

    Time frame: 12 months from vascular intervention

  5. Additional secondary endpoint- Foot Necrosis

    Development of necrosis in the treated limb within the study period. Unit of Measure: Number of participants and number of limbs

    Time frame: 12 months from vascular intervention

  6. Additional secondary endpoint- Minor Amputation

    Minor amputation defined as amputation within the foot (below the ankle). Unit of Measure: Number of participants and number of limbs

    Time frame: 12 months from vascular intervention

  7. Additional secondary endpoint- Heart Failure Hospitalization

    Hospital admission with a primary diagnosis of heart failure. Unit of Measure: Number of participants

    Time frame: 12 months from vascular intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — only IPD used in the results publication

Supporting information: Study protocol

Time frame: Individual participant data (de-identified) and supporting documents will be available upon reasonable request from qualified researchers, starting 6 months after publication of the primary results and for a period of 5 years.

Access criteria: Anonymized individual participant data (IPD) may be shared upon reasonable request. Access will be considered for qualified researchers with a valid scientific proposal. Requests will be reviewed by the study team, and a data sharing agreement may be required.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2025
First posted
Sep 5, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07157475
Lead sponsor
Wroclaw Medical University
Collaborators
Poznan University of Medical Sciences, Military Institute od Medicine National Research Institute
Responsible party
Edyta Sutkowska (M.D., Ph.D., Wroclaw Medical University) — Principal investigator
First posted
Sep 5, 2025
Start date
Jul 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 23, 2026

Study contacts

Edyta Sutkowska, M.D., Ph.D.
Contact
edyta.sutkowska@umw.edu.pl
48503077016
Edyta Sutkowska, Ph.D
study chair · Wroclaw Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion